Skip to main content
Top

17-02-2017 | Glioblastoma multiforme | Article

On glioblastoma and the search for a cure: where do we stand?

Journal: Cellular and Molecular Life Sciences

Authors: John Bianco, Chiara Bastiancich, Aleksander Jankovski, Anne des Rieux, Véronique Préat, Fabienne Danhier

Publisher: Springer International Publishing

Abstract

Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term “glioblastoma multiforme”. Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today. Current treatments are far from satisfactory with poor prognosis, and focus on palliative management rather than curative intervention. However, therapeutic research leading to developments in novel treatment stratagems show promise in combating this disease. Here we present a review on GBM, looking at the history and advances which have shaped neurosurgery over the last century that cumulate to the present day management of GBM, while also exploring future perspectives in treatment options that could lead to new treatments on the road to a cure.
Literature
1.
Jones E (1999) Colgi, Cajal and the neuron doctrine. J Hist Neurosci 8(2):170–178PubMedCrossRef
2.
Bock O (2013) Cajal, Golgi, Nansen, Schäfer and the neuron doctrine. Endeavour 37(4):228–234PubMedCrossRef
3.
DeAngelis L, Mellinghoff I (2011) Virchow 2011 or how to ID(H) human glioblastoma. J Clin Oncol 29(34):4473–4474PubMedCrossRef
4.
Scherer H (1940) A critical review: the pathology of cerebral gliomas. J Neurol. Psychiatry 3(2):147–177
5.
Baker Fn (1993) The Massachusetts General Hospital. Early history and neurosurgery to 1939. J Neurosurg 79(6):948–959CrossRef
6.
Lister J (1867) On the antiseptic principle in the practice of surgery. The British Medical Journal 2:246–248PubMedCrossRef
7.
Kerr P, Caputy A, Horwitz N (2005) A history of cerebral localization. Neurosurg Focus 18 (4):e1PubMedCrossRef
8.
Greenblatt S (1997) The crucial decade: modern neurosurgery’s definitive development in Harvey Cushing’s early research and practice, 1900 to 1910. J Neurosurg 87(6):964–971PubMedCrossRef
9.
Macewen W (1881) Intra-cranial lesions: illustrating some points in connexion with the localisation of cerebral affections and the advantages of antiseptic trephining. Lancet 118(3031):581–583CrossRef
10.
Greenblatt S (2007) A surgeon for the brain. Brain 130(1):303–306CrossRef
11.
Macewen W (1879) Tumour of the dura mater; convulsions; removal of tumour by trephining; recovery. Glasgow Med J 12:208–213
12.
Bennet A, Godlee R (1885) Case of a cerebral tumour. Med Chir Trans 68:243–275CrossRef
13.
Kirkpatrick D (1984) The first primary brain-tumor operation. J Neurosurg 61(5):809–813PubMedCrossRef
14.
Greenblatt S (2003) Harvey Cushing’s paradigmatic contribution to neurosurgery and the evolution of his thoughts about specialization. Bull Hist Med 77(4):789–822PubMedCrossRef
15.
Horsley V (1887) Remarks on ten consecutive cases of operations upon the brain and cranial cavity to illustrate the details and safety of the method employed. Br Med J 1(1373):863–865PubMedPubMedCentralCrossRef
16.
Horsley V (1886) Brain surgery. Br Med J 2(1345):670–675CrossRef
17.
Tan T, Black P (2002) Sir Victor Horsley (1857–1916): pioneer of neurological surgery. Neurosurgery 50(3):607–611PubMed
18.
Toledo-Pereyra L (2009) X-rays surgical revolution. J Invest Surg 22(5):327–332PubMedCrossRef
19.
Voorhees J, Cohen-Gadol A, Spencer D (2005) Early evolution of neurological surgery: conquering increased intracranial pressure, infection, and blood loss. Neurosurg Focus 18(4):e2PubMedCrossRef
20.
Dandy W (1918) Ventriculography following the injection of air into the cerebral ventricles. Ann Surg 68(1):5–11PubMedPubMedCentralCrossRef
21.
Ferguson S, Lesniak M (2005) Percival Bailey and the classification of brain tumors. Neurosurg Focus 18(4):e7PubMedCrossRef
22.
Bailey O (1985) Genesis of the Percival Bailey-Cushing classification of gliomas. Pediatr Neurosci 12(4–5):261–265PubMed
23.
Globus J, Strauss I (1925) Spongioblastoma multiforme. A primary malignant from of brain neoplasm: its clinical and anatomic features. Arch Neurol Psychiatr 14 (2):139–191
24.
Bailey P, Cushing H (1925) Medulloblastoma Cerebelli. A common type of midcerebellar glioma of childhood. Arch Neurol Psychiatr 14 (2):192–224CrossRef
25.
Bailey P, Cushing H (1926) A classification of the tumors of the Glioma group on histogenetic basis with correlated study of prognosis. JB Lipponcott, Philadelphia
26.
Scheithauer B (2008) Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol 19(4):551–564CrossRef
27.
Canale D, Longo L (1990) Harvey Cushing and pediatric neurosurgery. Neurosurgery 27(4):602–610PubMedCrossRef
28.
Bailey P (1927) Further remarks concerning tumors of the glioma group. Bull Johns Hopkins Hosp 40:354–389
29.
Bradač G, Büll U, Fahlbusch R, Grumme T, Kazner E, Kretzschmar K, Lanksch W, Meese W, Schramm J, Steinhoff H, Stochdorph O, Wende S (1982) Computed tomography in intracranial tumors: differential diagnosis and clinical aspects. Springer, BerlinCrossRef
30.
Bailey P (1933) Intracranial tumors. C.C. Thomas, Springfield
31.
Penfield W (1931) The classification of gliomas and neuroglia cell types. Arch Neurol Psychiatr 26 (4):745–753CrossRef
32.
Zülch K (1981) Historical development of the classification of brain tumours and the new proposal of the World Health Organization (WHO). Neurosurg Rev 4(3):123–127PubMedCrossRef
33.
Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772PubMedCrossRef
34.
Peiffer J, Kleihues P (1999) Hans-Joachim Scherer (1906–1945), pioneer in glioma research. Brain Pathol 9(2):241–245PubMedCrossRef
35.
Scherer H (1940) Cerebral astrocytomas and their derivatives. Am J Cancer 40(2):159–198
36.
Lee K, Choe G, Nam K, Seo A, Yun S, Kim K, Cho H, Park S (2013) Immunohistochemical classification of primary and secondary glioblastomas. Korean J Pathol 47(6):541–548PubMedPubMedCentralCrossRef
37.
Spiegel E, Wycis H, Marks M, Lee A (1947) Stereotaxic apparatus for operations on the human brain. Science 106(2754):349–350PubMedCrossRef
38.
Uluç K, Kujoth G, Başkaya M (2009) Operating microscopes: past, present, and future. Neurosurg Focus 27(3):e4PubMedCrossRef
39.
Sachs S (1950) The problem of glioblastomas. J Neurosurg 7(3):185–189PubMedCrossRef
40.
Zülch K (1986) Brain tumours. Their biology and pathology. 3rd edn. Springer, Berlin
41.
Netsky M, August B, Fowler W (1950) The longevity of patients with glioblastoma multiforme. J Neurosurg 7(3):261–269PubMedCrossRef
42.
Delgado-López P, Corrales-García E (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18(11):1062–1072PubMedCrossRef
43.
Mut M, Lopes M, Shaffrey M (2005) Lucien J. Rubinstein: enduring contributions to neuro-oncology. Neurosurg Focus 18(4):e8PubMedCrossRef
44.
Roth J, Elvidge A (1960) Glioblastoma multiforme: a clinical survey. J Neurosurg 17(4):736–750PubMedCrossRef
45.
Lindquist C (1995) Gamma knife radiosurgery. Semin Radiat Oncol 5(3):197–202PubMedCrossRef
46.
Yanagihara T, Saadatmand H, Wang T (2016) Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. J Neurooncol 130:397–411. doi:10.​1007/​s11060-016-2270-2 PubMedCrossRef
47.
Hounsfield G (1973) Computerized transverse axial scanning (tomography). 1. Description of system. Br J Radiol 46(552):1016–1022PubMedCrossRef
48.
Lauterbur P (1973) Image formation by induced local interactions: examples of employing nuclear magnetic resonance. Nature 242:190–191CrossRef
49.
Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62(10):2152–2165PubMedCrossRef
50.
Zülch K (1980) Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology 19(2):59–66PubMedCrossRef
51.
Buckner J, Brown P, O’Neill B, Meyer F, Wetmore C, Uhm J (2007) Central nervous system tumors. Mayo Clin Proc 82(10):1271–1286PubMedCrossRef
52.
Agnihotri S, Burrell K, Wolf A, Jalali S, Hawkins C, Rutka J, Zadeh G (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 61(1):25–41CrossRef
53.
Dandy W (1928) Removal of right cerebral hemisphere for certain tumors with hemiplegia: preliminary report. J Am Med Assoc 90(11):823–825CrossRef
54.
Wright J, Chugh J, Wright C, Alonso F, Hdeib A, Gittleman H, Barnholtz-Sloan J, Sloan A (2016) Laser interstitial thermal therapy followed by minimal-access transsulcal resection for the treatment of large and difficult to access brain tumors. Neurosurg Focus 41(4):e14PubMedCrossRef
55.
Hervey-Jumper S, Berger M (2016) Maximizing safe resection of low- and high-grade glioma. J Neurooncol 130:269–282PubMedCrossRef
56.
Yong R, Lonser R (2011) Surgery for glioblastoma multiforme: striking a balance. World Neurosurg 76 (6):528–530PubMedPubMedCentralCrossRef
57.
Young R, Jamshidi A, Davis G, Sherman J (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 3(9):121PubMedPubMedCentral
58.
Smets T, Lawson T, Grandin C, Jankovski A, Raftopoulos C (2013) Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol 23(6):1467–1477PubMedCrossRef
59.
Mirimanoff R, Gorlia T, Mason W, van den Bent M, Kortmann R, Fisher B, Reni M, Brandes A, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569PubMedCrossRef
60.
Patel D, Agarwal N, Tomei K, Hansberry D, Goldstein I (2015) Optimal timing of whole-brain radiation therapy following craniotomy for cerebral malignancies. World Neurosurg 84 (2):412–419PubMedCrossRef
61.
Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):93–101CrossRef
62.
Corso C, Bindra R (2016) Success and failures of combined modalities in glioblastoma multiforme: old problems and new directions. Semin Radiat Oncol 26(4):281–298PubMedCrossRef
63.
Ehrlich P (1913) Address in pathology on chemotherapeutics: scientific principles, methods, and results. Lancet 2(5694):445–451
64.
Krumbhaar E, Krunbhaar H (1919) The blood and bone barrow in yellow cross gas (mustard gas) poisoning. J Med Res 40(3):497–508PubMedPubMedCentral
65.
Krumbhaar E (1919) Rôle of the blood and bone marrow in certain forms of gas poisoning: I. Peripheral blood changes and their significance. J Am Med Assoc 72(1):39–41CrossRef
66.
Fenn J, Udelsman R (2011) First use of intravenous chemotherapy cancer treatment: rectifying the record. J Am Coll Surg 212(3):413–417PubMedCrossRef
67.
Thomas R, Recht L, Nagpal S (2013) Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol 5:1–9PubMed
68.
Connors T (1996) Anticancer drug development: the way forward. Oncologist 1(3):180–181PubMed
69.
Deeken J, Löscher W (2007) The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13(6):1663–1674PubMedCrossRef
70.
Rubin P, Gash D, Hansen J, Nelson D, Williams J (1994) Disruption of the blood–brain barrier as the primary effect of CNS irradiation. Radiother Oncol 31(1):51–60PubMedCrossRef
71.
Muldoon L, Soussain C, Jahnke K, Johanson C, Siegal T, Smith Q, Hall W, Hynynen K, Senter P, Peereboom D, Neuwelt E (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25(16):2295–2305PubMedCrossRef
72.
Cohen M, Shen Y, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131–1138PubMedCrossRef
73.
Ashby L, Smith K, Stea B (2016) Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol 14(1):225PubMedPubMedCentralCrossRef
74.
Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke P, Whittle I, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5 (2):79–88PubMedPubMedCentral
75.
Bock H, Puchner M, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt S, Rohde V, Giese A (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33(4):441–449PubMedPubMedCentralCrossRef
76.
Brem H, Piantadosi S, Burger P, Walker M, Selker R, Vick N, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Clifford Schold S, Group P-BTT (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345(8956):1008–1012PubMedCrossRef
77.
Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H (2001) Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 6(Suppl 4):12–16PubMedCrossRef
78.
Liu G, Franssen E, Fitch M, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115PubMedCrossRef
79.
Brada M, Stenning S, Gabe R, Thompson L, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins V, Lee S (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28(30):4601–4608PubMedCrossRef
80.
Silber J, Bobola M, Blank A, Chamberlain M (2012) O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta 1826(1):71–82PubMedPubMedCentral
81.
Prados M, Byron S, Tran N, Phillips J, Molinaro A, Ligon K, Wen P, Kuhn J, Mellinghoff I, de Groot J, Colman H, Cloughesy T, Chang S, Ryken T, Tembe W, Kiefer J, Berens M, Craig D, Carpten J, Trent J (2015) Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology 17(8):1051–1063PubMedPubMedCentralCrossRef
82.
Davies A, Weinberg U, Palti Y (2013) Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci 1291:86–95PubMedCrossRef
83.
Taillibert S, Le Rhun E, Chamberlain M (2015) Tumor treating fields: a new standard treatment for glioblastoma? Curr Opin Neurol 28(6):659–664PubMedCrossRef
84.
Domingo-Musibay E, Galanis E (2015) What next for newly diagnosed glioblastoma? Future Oncol 11(24):3273–3283PubMedPubMedCentralCrossRef
85.
Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V, Kirson E, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano J, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi J, Payer F, Mehdorn M, Weil R, Pannullo S, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin P (2012) NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48(14):2192–2202PubMedCrossRef
86.
Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28(12):188–189CrossRef
87.
Desjardins A (2015) Neuro-oncology: what is the optimal use of bevacizumab in glioblastoma? Nat Rev Neurol 11(8):429–430PubMedCrossRef
88.
Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown P, Jaeckle K, Schiff D, Stieber V, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman E, Aldape K, Curran WJ, Mehta M (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708PubMedPubMedCentralCrossRef
89.
Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier A, Hoang-Xuan K, Kavan F, Cernea D, Brandes A, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722PubMedCrossRef
90.
Wick W, Chinot O, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology 18 (10):1434–1441PubMedCrossRef
91.
Chinot O, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology 18(9):1313–1318PubMedCrossRef
92.
Rose S (2011) FDA pulls approval for Avastin in breast cancer. Cancer Discov 1(7):1–2
93.
Kovic B, Xie F (2015) Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol 33(20):2296–2302PubMedCrossRef
94.
Campos B, Olsen L, Urup T, Poulsen H (2016) A comprehensive profile of recurrent glioblastoma. Oncogene 35:5819–5825PubMedCrossRef
95.
Sun H, Du S, Liao G, Xie X, Ren C, Yuan Y (2015) Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens? A meta-analysis. Medicine (Baltimore) 94(20):e827CrossRef
96.
Tosoni A, Franceschi E, Poggi R, Brandes A (2016) Relapsed glioblastoma: treatment strategies for initial and subsequent recurrences. Curr Treat Options Oncol 17(9):49PubMedCrossRef
97.
Yin A, Cheng J, Zhang X, Liu B (2013) The treatment of glioblastomas: a systematic update on clinical Phase III trials. Crit Rev Oncol Hematol 87(3):265–282PubMedCrossRef
98.
clinicaltrials.gov National Library of Medicine (US) Accessed 31 Oct 2016
99.
Tavano L, Muzzalupo R (2016) Multi-functional vesicles for cancer therapy: the ultimate magic bullet. Colloids Surfaces B 147:161–171CrossRef
100.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R, Ludwin S, Allgeier A, Fisher B, Belanger K, Hau P, Brandes A, Gijtenbeek J, Marosi C, Vecht C, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross J, Mirimanoff R, Groups EOfRaToCBTaRO, Group NCIoCCT (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef
101.
Scott J, Bauchet L, Fraum T, Nayak L, Cooper A, Chao S, Suh J, Vogelbaum M, Peereboom D, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey L, DeAngelis L, Shih J, Iwamoto F (2012) Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 118(22):5595–5600PubMedPubMedCentralCrossRef
102.
Neagu M, Reardon D (2015) An update on the role of immunotherapy and vaccine strategies for primary brain tumors. Curr Treat Options Oncol 16(11):54PubMedCrossRef
103.
Sampson J, Mitchell D (2015) Vaccination strategies for neuro-oncology. Neuro-Oncology 17 (7):15–25CrossRef
104.
Ardon H, Van Gool S, Lopes I, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F, De Vleeschouwer S (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99(2):261–272PubMedCrossRef
105.
Schijns V, Pretto C, Devillers L, Pierre D, Hofman F, Chen T, Mespouille P, Hantos P, Glorieux P, Bota D, Stathopoulos A (2015) First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine 33(23):269–2696CrossRef
106.
Reijneveld J, Voest E, Taphoorn M (2000) Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 247(8):597–608PubMedCrossRef
107.
Scaringi C, Enrici R, Minniti G (2013) Combining molecular targeted agents with radiation therapy for malignant gliomas. Onco Targets Ther 6:1079–1095PubMedPubMedCentral
108.
McGee M, Hamner J, Williams R, Rosati S, Sims T, Ng C, Gaber M, Calabrese C, Wu J, Nathwani A, Duntsch C, Merchant T, Davidoff A (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76(5):1537–1545PubMedPubMedCentralCrossRef
109.
Gupta V, Jaskowiak N, Beckett M, Mauceri H, Grunstein J, Johnson R, Calvin D, Nodzenski E, Pejovic M, Kufe D, Posner M, Weichselbaum R (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8(1):47–54PubMedCrossRef
110.
Bolderson E, Richard D, Zhou B, Khanna K (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15(20):6314–6320PubMedCrossRef
111.
Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293–301PubMedPubMedCentralCrossRef
112.
Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin N, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 343(7035):913–917CrossRef
113.
Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T, Santarosa M, Dillon K, Hickson I, Knights C, Martin N, Jackson S, Smith G, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921PubMedCrossRef
114.
Powell C, Mikropoulos C, Kaye S, Nutting C, Bhide S, Newbold K, Harrington K (2010) Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36(7):566–575PubMedCrossRef
115.
Senra J, Telfer B, Cherry K, McCrudden C, Hirst D, O’Connor M, Wedge S, Stratford I (2011) Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10(10):1949–1958PubMedPubMedCentralCrossRef
116.
Bonnet D, Dick J (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 3(7):730–737PubMedCrossRef
117.
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19):7011–7021PubMedCrossRef
118.
Beier D, Röhrl S, Pillai D, Schwarz S, Kunz-Schughart L, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier C (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68(14):5706–5715PubMedCrossRef
119.
Hegi M, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros J, Hainfellner J, Mason W, Mariani L, Bromberg J, Hau P, Mirimanoff R, Cairncross J, Janzer R, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003PubMedCrossRef
120.
Lathia J, Mack S, Mulkearns-Hubert E, Valentim C, Rich J (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217PubMedPubMedCentralCrossRef
121.
Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R, Lander E (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4):645–659PubMedPubMedCentralCrossRef
122.
Qin L, Jia P, Zhang Z, Zhang S (2015) ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis. J Exp Clin Canc Res 34:57CrossRef
123.
Calzolari A, Saulle E, De Angelis M, Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M, Testa U (2014) Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS One 9(4):e94438PubMedPubMedCentralCrossRef
124.
Pardridge W (2007) Blood–brain barrier delivery. Drug Discov Today 12(1–2):54–61PubMedCrossRef
125.
Vogelbaum M, Aghi M (2015) Convection-enhanced delivery for the treatment of glioblastoma. Neuro-Oncology 17 (Suppl 2):3–8CrossRef
126.
Hynynen K, McDannold N, Vykhodtseva N, Jolesz F (2003) Non-invasive opening of BBB by focused ultrasound. Acta Neurochir Suppl 86:555–558PubMed
127.
Choi J, Feshitan J, Baseri B, Wang S, Tung Y, Borden M, Konofagou E (2010) Microbubble-size dependence of focused ultrasound-induced blood–brain barrier opening in mice in vivo. IEEE Trans Bio-Med Eng 57(1):145–154CrossRef
128.
Liu H, Hsu P, Lin C, Huang C, Chai W, Chu P, Huang C, Chen P, Yang L, Kuo J, Wei K (2016) Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology 281(1):99–108PubMedCrossRef
129.
Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon J, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre J, Idbaih A (2016) Clinical trial of blood–brain barrier disruption by pulsed ultrasound. Sci Transl Med 8 (343):343re342
130.
Sarkar G, Curran G, Sarkaria J, Lowe V, Jenkins R (2014) Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. PLoS One 9(5):e97655PubMedPubMedCentralCrossRef
131.
Allen T, Cullis P (2004) Drug delivery systems: entering the mainstream. Science 303(5665):1818–1822PubMedCrossRef
132.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760PubMedCrossRef
133.
Gutkin A, Cohen Z, Peer D (2016) Harnessing nanomedicine for therapeutic intervention in glioblastoma. Expert Opin Drug Deliv 13(11):1573–1582PubMedCrossRef
134.
Kim S, Harford J, Pirollo K, Chang E (2015) Effective treatment of glioblastoma requires crossing the blood–brain barrier and targeting tumors including cancer stem cells: the promise of nanomedicine. Biochem Biophys Res Commun 468(3):485–489PubMedPubMedCentralCrossRef
135.
Danhier F, Messaoudi K, Lemaire L, Benoit J, Lagarce F (2015) Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. Int J Pharm 481(1–2):154–161PubMedCrossRef
136.
Bastiancich C, Vanvarenberg K, Ucakar B, Pitorre M, Bastiat G, Lagarce F, Préat V, Danhier F (2016) Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J Control Release 225:283–293PubMedCrossRef
137.
Hoare T, DS K (2008) Hydrogels in drug delivery: progress and challenges. Polymer 49(8):1993–2007CrossRef
138.
Bastiancich C, Danhier P, Préat V, Danhier F (2016) Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. J Control Release 243:29–42PubMedCrossRef
139.
Vellimana A, Recinos V, Hwang L, Fowers K, Li K, Zhang Y, Okonma S, Eberhart C, Brem H, Tyler B (2013) Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J Neurooncol 111(3):229–236PubMedCrossRef
140.
Fourniols T, Randolph L, Staub A, Vanvarenberg K, Leprince J, Préat V, des Rieux A, Danhier F (2015) Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. J Control Release 210:95–104PubMedCrossRef
141.
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56(4):275–287PubMedCrossRef
142.
Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C (2015) Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One 10(10):e0140131PubMedPubMedCentralCrossRef
143.
Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent M, Wick W, Hegi M (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6(1):39–51PubMedCrossRef
144.
Parker N, Khong P, Parkinson J, Howell V, Wheeler H (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol 5:55PubMedPubMedCentral
145.
Messaoudi K, Clavreul C, Danhier F, Saulnier P, Benoît J-P, Lagarce F (2015) Combined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomide. Eur J Nanomed 7(2):97–107CrossRef
146.
Kaina B, Margison G, Christmann M (2010) Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 67(21):3663–3681PubMedCrossRef
147.
Ramirez Y, Mladek A, Phillips R, Gynther M, Rautio J, Ross A, Wheelhouse R, Sakaria J (2015) Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther 14(1):111–119PubMedCrossRef
148.
Rich J, Bigner D (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3(5):430–446PubMedCrossRef
149.
Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool S, De Vleeschouwer S (2014) Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 134(4):873–884PubMedCrossRef
150.
Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F (2010) Galectins and gliomas. Brain Pathol 20(1):17–27PubMedPubMedCentralCrossRef
151.
Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius H, Kiss R (2005) Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335(1):27–35PubMedCrossRef